Top US Investor Steven F. Mayer becomes shareholder of Syntellix and will join Supervisory Board

Hannover (ots) - Important step for company´s North American
strategy - Syntellix investor base now extends from Los Angeles to
Singapore

Syntellix AG, a fast-growing medical technology innovator that is
in the process of disrupting the global orthopaedic implant market
using patent-protected magnesium technology based on its innovations
in material science and biomedical engineering, today announced that
well-known US private equity investor Steven F. Mayer has become a
shareholder. In addition to his role as an investor, Mr. Mayer has
agreed to join the Supervisory Board of the company. Syntellix core
products have obtained product registration in approximately 50
countries, including the EU, and Syntellix is preparing for an IPO to
exploit the enormous market potential of its technology not only in
the area of orthopaedic and trauma surgery, but also in the fields of
neurosurgery, dental, craniomaxillofacial, and other medical
applications.

Until recently, Mr. Mayer was senior managing director, co-head of
global private equity, and chairman of the investment committee of
Cerberus Capital Management, L.P., one of the world's leading private
investment firms with approximately US$ 34 billion of capital under
management. Mr. Mayer, who has over 20 years' experience in private
equity investing across a wide variety of industries, has served on
numerous boards of directors (or similar governing bodies) of public
and private health care and other companies. He is a graduate of
Princeton University and Harvard Law School.

Syntellix CEO, founder and main shareholder Prof. Dr. Utz Claassen
stated, "We are pleased to welcome Mr. Mayer as a shareholder and
future member of the Supervisory Board. It is both a pleasure and an
honor for us to have a world class professional of his experience and
reputation help us utilize and develop the unique potential of our
innovations for the benefit of patients, doctors, and health systems
around the world. Syntellix products have already been used
successfully in thousands of surgeries, and the unique
characteristics of our products can translate into better surgical
outcomes, fewer follow-on procedures, and substantially lower cost to
payors. Mr. Mayer's arrival comes exactly at the right time, as his
strategic and capital markets expertise, combined with the
operational and financial rigour he will add to our Supervisory
Board, can bring significant value to Syntellix as we prepare to go
public and continue our rapid expansion."

About Syntellix:

Syntellix AG is an internationally operating, dynamically growing
medical technology company, headquartered in Hannover (Germany). The
company specializes in research, development, marketing and
distribution of highly innovative transformable metallic implants.
The products, which are made of the patented material MAGNEZIX®, are
unique and, in a recent publication, have been found to be clinically
superior compared with common titanium implants. They degrade in the
body and are converted into endogeneous bone tissue while providing a
favourable combination of stability, elasticity and bioabsorbability.
Syntellix AG is the global market and technology leader in the area
of bioabsorbable metallic orthopaedic implants and has already been
honored with many major awards and prizes, including the Innovation
Prize of the German Economy 2012/13, the Future Prize of the Health
Industry Club 2016, the German Medical Award 2017, the STEP Award
2017, and it has also been honored as "Innovator of the Year 2017" in
Germany. Syntellix founder Utz Claassen himself received the award as
"Most Innovative Entrepreneur International 2016" from the hands of
EU Commissioner Günther Oettinger, not least for his work for
Syntellix.

Contact:
Ms. Caroline Meyer-Maltseva
Press Relations
T: +49 (0)511 270413-55
presse@syntellix.com
www.syntellix.com

Syntellix AG
Aegidientorplatz 2a
30159 Hanover
Germany

Original-Content von: Syntellix AG, übermittelt durch news aktuell